Research programme: cytomegalovirus monoclonal antibodies - Stadius Biopharma
Latest Information Update: 28 Oct 2024
At a glance
- Originator Stadius Biopharma
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Cytomegalovirus infections
Highest Development Phases
- No development reported Cytomegalovirus infections
Most Recent Events
- 28 Oct 2024 No recent reports of development identified for preclinical development in Cytomegalovirus infections in USA (Parenteral)
- 28 Oct 2024 No recent reports of development identified for preclinical development in Cytomegalovirus infections(Prevention) in USA (Parenteral)
- 30 Sep 2020 Preclinical trials in Cytomegalovirus infections (Prevention) in USA (Parenteral) (Stadius Biopharma pipeline, September 2020)